Effect of GP IIb/IIIa inhibitor duration on the clinical prognosis of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction with no-/slow-reflow phenomenon

Hu, Xiangming; Wang, Weimian; Ye, Jingguang; Yu, Bingyan; Zhou, Langping; Zhou, Yingling; Dong, Haojian

doi:10.1016/j.biopha.2021.112196

Cited by 5 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Given the lack of sufficient and reliable clinical data to validate standard treatment for GPIs, the 2021 ACC guidelines merely recommend intravenous administration of GPIs for at least 18 h in high-risk or thrombus-burdened situations (class IIa) [ 29 , 30 ]. In terms of maintenance time, the latest research showed that the maintenance time of tirofiban for <24 h and ≥24 h had similar clinical effects, there was no significant difference in the incidence of MACE, cardiac function, and in-hospital bleeding events between the two groups of patients, indicating that the maintenance time of tirofiban can be appropriately shortened [ 42 ]. Nevertheless, there is no recommendation for a specific route of administration and further exploration of specific methods of use is needed to maximize clinical benefits, therefore, we conducted this meta-analysis to find the more efficient and safer administration of tirofiban.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of intracoronary versus intravenous tirofiban in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A meta-analysis of randomized controlled trials

Tian¹,

Liu²,

Zhang³

et al. 2023

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of intracoronary versus intravenous tirofiban in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A meta-analysis of randomized controlled trials

Tian¹,

Liu²,

Zhang³

et al. 2023

Heliyon

View full text Add to dashboard Cite

“…There were no significant differences in bleeding events between the two groups in 30 days and 180 days. [35] A total of 127 patients were divided into two groups based on the duration of tirofiban use (less and more than 24 h) in a cohort study. [36] There was no significant difference between two groups in terms of baseline characteristics, plaque condition, and coronary physiological function.…”

Section: Advances In the Treatment Of Cadmentioning

confidence: 99%

Epidemiology and current management of cardiovascular disease in China

2024

Journal of Geriatric Cardiology

View full text Add to dashboard Cite

The Annual Report on Cardiovascular Health and Diseases in China (2022) intricate landscape of cardiovascular health in China. This is the fourth section of the report with a specific focus on epidemiology and current management of cardiovascular disease (CVD) in China. This section of the report highlights the epidemiological trends of CVD in China. It reveal a concerning rise in prevalence, with approximately 330 million affected individuals, including significant numbers with stroke, coronary artery disease (CAD), heart failure, and other conditions. CVD stands as the primary cause of mortality among both urban and rural populations, accounting for nearly half of all deaths in 2020. Mortality rates are notably higher in rural areas compared to urban centers since 2009. While age-standardized mortality rates have decreased, the absolute number of CVD deaths has increased, primarily due to population aging. Ischemic heart disease, hemorrhagic and ischemic strokes are the leading causes of CVD-related deaths. Notably, the burden of atherosclerotic cardiovascular disease has risen substantially, with atherosclerotic cardiovascular disease-related deaths increasing from 1990 to 2016. The incidence of ischemic stroke and ischemic heart disease has shown similar increasing trends over the past three decades. CAD mortality, particularly acute myocardial infarction, has been on the rise, with higher mortality rates observed in rural areas since 2016. The prevalence of CAD has increased significantly, with over 11 million patients identified in 2013. Studies assessing hospital performance in managing acute coronary syndrome reveal gaps in adherence to guideline-recommended strategies, with disparities in care quality across hospitals. However, initiatives like the China Patient-centered Evaluative Assessment of Cardiac Events (PEACE)-Retrospective AMI Study and the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome (CCC-ACS) project aim to improve patient outcomes through enhanced care protocols. Moreover, advancements in medical technology, such as quantitative flow ratio-guided lesion selection during percutaneous coronary intervention, show promise in improving clinical outcomes for patients undergoing intervention.

show abstract

“…Ингибиторы Gp IIb/IIIa, фактически продемонстрировали преимущества в клиническом исходе у пациентов с острым инфарктом миокарда, в сложных плановых процедурах чрескожного коронарного вме- [61,62]. Тем не менее, обнаружилось наличие индивидуальных вариаций в ответе на абциксимаб, что может приводить к неблагоприятным клиническим последствиям [63].…”

Section: Reviewunclassified

The role of the T1565C gene polymorphism encoding integrin beta 3 in the development of thrombotic events and its influence on the efficiency of anti-platelet therapy

Изможерова,

Попов,

Антропова

et al. 2023

Zhurnal «Patologicheskaia Fiziologiia I Eksperimental`naia Terapiia»

View full text Add to dashboard Cite

В обзоре анализируются современные представления о структурно-функциональных особенностях интегринов у человека; исследования связи между полиморфизмом гена T1565C, кодирующего интегрин бета‑3 (ITGβ3), тромботических явлений и эффективностью применяемых антитромбоцитарных препаратов; рассмотрена целесообразность исследования на наличие данного полиморфизма. Анализ проведен на основе публикаций, представленных в базах данных и web-ресурсах: MEDLINE, PubMed, Google Scholar, Cyberleninka, электронной библиотеке eLibrary, охватывающих временной период с 1989 по 2022 г. Критериями включения в обзор являлись статьи на русском и английском языках, результаты когортных и рандомизированных исследований, мета-анализов, систематические обзоры исследуемой проблемы, а также описания клинических случаев. Критериями исключения из выборки послужили исследования с отсутствием четко сформулированных выводов или наличием противоречивых результатов. This review describes the main modern provisions on the structural and functional features of integrins in humans; studies of the relationship between polymorphism of the T1565C gene encoding integrin beta 3 (ITGβ3), thrombotic events and the effectiveness of antiplatelet drugs used; the expediency of research for the presence of this polymorhism is considered. Data analysis was carried out on the basis of publications presented in databases and web resources: MEDLINE, PubMed, Google Scholar, Cyberleninka, eLibrary, covering the time period from 1989 to 2022. The inclusion criteria for the review were articles in Russian and English, results of cohort and randomized studies, meta-analyses, systematic reviews of the problem under study, as well as descriptions of clinical cases. Exclusion criteria were studies with no clear-cut conclusions or conflicting results.

show abstract

Effect of GP IIb/IIIa inhibitor duration on the clinical prognosis of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction with no-/slow-reflow phenomenon

Cited by 5 publications

References 37 publications

Efficacy and safety of intracoronary versus intravenous tirofiban in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A meta-analysis of randomized controlled trials

Efficacy and safety of intracoronary versus intravenous tirofiban in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A meta-analysis of randomized controlled trials

Epidemiology and current management of cardiovascular disease in China

The role of the T1565C gene polymorphism encoding integrin beta 3 in the development of thrombotic events and its influence on the efficiency of anti-platelet therapy

Contact Info

Product

Resources

About